Management of Lung Nodules

Classification and Management

The American College of Radiology recommends that lung nodules are categorized based on size and characteristics, with larger nodules (≥8mm) requiring more aggressive evaluation and smaller nodules often appropriate for surveillance imaging 1, 2, 3
Part-solid nodules (containing both ground-glass and solid components) carry higher malignancy risk than pure solid nodules, especially when the solid component is ≥8 mm 3, 4

For nodules with low probability of malignancy (<10%), the American College of Chest Physicians recommends CT surveillance in 3-6 months 5, 4
For nodules with intermediate probability (10-25%), CT surveillance in 3-6 months is acceptable, though pre-COVID recommendations suggested PET/CT or biopsy 2, 3
For nodules with high probability (65-85%), evaluation with PET scan and/or nonsurgical biopsy is recommended 6, 4
For nodules with very high probability (>85%), proceeding directly to treatment (surgical resection or stereotactic radiotherapy) without further diagnostic testing is appropriate 6, 4

Patient risk factors (smoking history, age, prior malignancy) should be incorporated into decision-making 7, 6, 4
If prior imaging is available, evidence of slow growth may allow for delayed evaluation or treatment 6, 4
For patients with life-limiting comorbidities, aggressive evaluation of small nodules may not be beneficial 7
The American College of Radiology recommends that CT surveillance use low-dose, non-contrast techniques with thin-section imaging to minimize radiation exposure while maintaining accuracy 7

Each nodule should be evaluated individually rather than assuming all are either metastatic or benign 8
For multiple small nodules, base follow-up frequency and duration on the size of the largest nodule 7
Do not deny curative treatment to patients with a dominant suspicious nodule and additional small nodules unless metastasis is confirmed by histopathology 8, 7

Patient preferences and values should be considered in management decisions 1, 3, 4

PET scans have poor sensitivity for nodules <8-10 mm due to limited spatial resolution and low mass of metabolically active cells, according to the American College of Chest Physicians 9
A negative PET scan in a 9 mm nodule does NOT provide sufficient reassurance to stop surveillance, as slow-growing malignancies and adenocarcinomas-in-situ frequently show false-negative PET results 9, 10
The American College of Chest Physicians specifically recommends against relying on PET for characterization of nodules in this size range 9

For intermediate-risk patients with a 9 mm solid nodule, repeat low-dose CT at 3 months, then 6 months, then 12 months, as recommended by the American College of Chest Physicians 10
Continue annual surveillance for up to 3 years if stable, with thin-section (≤1.5 mm), non-contrast CT technique 9, 10
Part-solid nodules >8 mm have significantly higher malignancy risk and warrant more aggressive management, with repeat CT at 3 months, then proceed to biopsy or surgical resection if it persists 9, 10, 11, 12

Continue annual CT surveillance for at least 3 years if the nodule remains stable, as recommended by the American College of Chest Physicians 9, 10
Some guidelines suggest extending surveillance beyond 3 years for part-solid or ground-glass components due to their indolent nature 10

The American College of Radiology recommends performing repeat CT at 3 months using low-dose, non-contrast technique with thin sections (≤1.5 mm) for solid nodules ≥8 mm with negative or mild PET uptake 13, 14
If the nodule persists at 3 months, the American College of Radiology suggests proceeding to nonsurgical biopsy (bronchoscopy or transthoracic needle biopsy) to establish tissue diagnosis 13, 14
For part-solid nodules >8 mm with negative PET, the American College of Radiology recommends repeat CT at 3 months, then proceeding directly to biopsy or surgical resection if the nodule persists, as PET should not be used to characterize part-solid lesions where the solid component measures ≥8 mm 14, 15
The American College of Radiology suggests proceeding directly to biopsy without 3-month surveillance if the probability of malignancy is 65-85% or higher based on clinical risk factors (age, smoking history, nodule characteristics) 13
For nodules with suspicious imaging features, such as spiculated borders, upper lobe location, or rapid growth on prior imaging, the American College of Radiology recommends proceeding directly to evaluation 14

The American College of Radiology recommends continuing CT surveillance at 6 months, 12 months, then annually for at least 3 years if biopsy is non-diagnostic or not feasible 14
The American College of Radiology suggests not stopping surveillance after one negative follow-up CT, but rather continuing monitoring for at least 3 years, as malignancies can declare themselves late 14